EFFECT OF COVID-19 DISEASE IN SMELL AND TASTE OF PATIENTS WITH MILD, MODERATE OR SEVERE SYMPTOMATOLOGY
NCT ID: NCT04657445
Last Updated: 2022-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2020-11-17
2021-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients
NCT04361565
Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia
NCT04388618
Smell and Taste Disorders in COVID-19 Patients
NCT04427332
Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection
NCT04354857
Retrospective Study on Anosmias and Ageusias Linked to Infection by Covid-19
NCT04681157
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study population will be divided in two groups. The first group will be consisted with positive patients that were referred to either the Emergency Department (ED) of Infectious Diseases or at the Outpatient Clinic screening for SARS-COV2 and are being self-quarantined at home. The participants will be hospitalized patients in the Infectious Diseases Unit (IDU) of the University General Hospital of Ioannina.
The examination will be performed at the moment of diagnosis both for self-quarantine patients and for in hospitalized patients. The follow up evaluation will be a re-examination, performed at least four weeks after the moment of diagnosis. The time internal of reassessing the patients chosen according to current literature, estimated that is the minimum reassessment interval and seems to be a reference time for either progression stabilization or recession of the symptoms of anosmia/ ageusia (12, 13).
Patients will be asked to evaluate their olfactory and gustatory abilities through the visual analogue scale (VAS), at three time points: 1.before infection( as they can recall it), 2. at the time of diagnosis and 3. four weeks later(14).
Patients' scoring will be recorded in a horizontal presentation of 100 VAS points, where zero refers to no smell or taste while 100 refers to normal sensation. In addition, patients will rate their nasal obstruction and rhinorrhea on a similar VAS scale, where 0 refers to a completely blocked nose and an excessively runny nose while 100 indicates normal nasal breathing and a no runny nose. All patients will assess the intensity of the olfactory and taste function, through a self testing them at home. Patients will rate from 0 to 100 the intensity of smell, after being exposed to five common household odors (ie lemon juice, oregano, instant coffee, toothpaste and mint gum).The choice of these substances is based on their influence at the irritation of the trigeminal nerve.
The intensity of taste function will be evaluated using four(4) substances: sugar, salt, lemon juice and instant coffee (decaffeinated), that represent the following 4 basic quality flavors:sweet, salty, sour and bitter. Every patient will have to receive orally half a teaspoon of each testant and report the quality of taste perception. After each testant they have to rinse their mouth with tap water. Bitter testant will have to be tested in the end.
Patient demographics, associated symptoms, and comorbidities will be recorded. The patients will have to report and fill in symptoms such as fever, cough, shortness of breath or dyspnea, fatigue, muscle aches, runny nose, blocked nose, loss of smell, and loss of taste.
The results will be recorded in a questionnaire.
Covid-19 positive patients recovering at home, will be informed for the study either by telephone or in person, following all the safety measures provided by National Organization of Public Health of Greece, by one of the investigators officially participating in the study. A questionnaire will be completed by the examinee, after telephone information about the purpose of the study and after providing a written consent from.
In hospitalized patients in the Infectious Diseases Unit, will be informed by the investigators participating in the study and will follow the above procedure.
This study was submitted for approval to the research ethic committee and the scientific council of University General Hospital of Ioannina and was accepted.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
home-quarantined patients
home-quarantined patients
visual analogue scale
A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
inhospitalized patients
inhospitalized patients
visual analogue scale
A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
visual analogue scale
A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* COVID-19 positive patient, via RT-PCR test
* Patient referred to the University General Hospital of Ioannina
Exclusion Criteria
* Previous nasal surgery, endoscopic sinus surgery
* Head and neck radiotherapy
* Head injury
* Allergic rhinitis
* Chronis Rhinosinusitis
* Psychiatric/ Neurological disorders
* Disorders that altering the level of consciousness (Glasgow Coma Scale \<15)
* History of smell and taste disorder
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Ioannina
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Liontos Angelos
CONSULTANT OF INTERNAL MEDICINE
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
CHARALAMPOS MILIONIS, PROFESSOR
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Ioannina
IOANNIS KASTANIOUDAKIS, PROFESSOR
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Ioannina
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University General Hospital of Ioannina
Ioannina, Epirus, Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
931/17-11-2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.